IP Library › Granted Patent US 12,433,889
Granted Patent B2
US 12,433,889 · App. 18/470,331 · Granted Oct 7, 2025

Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Inventors: Thomas Hofmann (Doylestown, PA); Stefan Ufer (Raleigh, NC); Kevin Stapleton (Laguna Beach, CA)
Assignee: Mannkind Corporation
A61K31/498A61K9/008A61K9/10A61K31/47A61K47/02A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,889
App. No.
18/470,331
Granted
Oct 7, 2025
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

Claims (44)

1. A pharmaceutical composition comprising:

a) a therapeutically effective dose of clofazimine or a pharmaceutically acceptable derivative or salt thereof;

b) a nonionic surfactant with a hydrophilic-lipophilic balance value of greater than c) an aqueous liquid carrier selected from at least one of: water, isotonic saline, buffered saline and aqueous electrolyte solutions; and

d) a mucolytic and/or biofilm destructing agent

wherein the clofazimine, or the pharmaceutically acceptable derivative or salt thereof, is provided in the form of particles in a suspension, and

wherein the particles of clofazimine, or the pharmaceutically acceptable derivative or salt thereof, have a median size of less than 5 μm and a D90 of less than 6 μm.

2. The pharmaceutical composition according to claim 1 wherein the particles of clofazimine, or the pharmaceutically acceptable derivative or salt thereof, have a mean size of less than 2 μm and a D90 of less than 3 μm.

3. The pharmaceutical composition according to claim 1 wherein said mucolytic and/or biofilm destructing agent is selected from the group consisting of at least one of: nebulized 4-7% hypertonic saline, metaperiodate, sodium dodecyl sulfate, sodium bicarbonate, tromethamine, silver nano particles, bismuth thiols, ethylene diamine tetraacetic acid, gentamicin loaded phosphatidylcholine-decorated gold nanoparticles, chelators, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides.

4. The pharmaceutical composition according to claim 1 wherein said mucolytic and/or biofilm destructing agent is an active agent selected from bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitine, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-amino salicylate, and mixtures thereof.

5. The pharmaceutical composition according to claim 1 , wherein the nonionic surfactant is selected from polysorbate 20, polysorbate 60, polysorbate 80, stearyl alcohol, a polyethylene glycol derivative of hydrogenated castor oil with an Hydrophilic-Lipophilic Balance value of 14 to 16, a polyethylene glycol derivative of hydrogenated castor oil with an Hydrophilic-Lipophilic Balance value of 15 to 17, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, polyoxyethylene (20) oleyl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (10) cetyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (100) stearyl ether, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (4) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (2) cetyl ether, caprylocaproyl polyoxyl-8 glyceride, polyethylene glycol (20) monostearate, polyethylene glycol (40) stearate, polyethylene glycol (100) stearate, polyethylene glycol (8) stearate, and polyoxyl 40 stearate, and mixtures thereof.

6. The pharmaceutical composition according to claim 1 , wherein the non-ionic surfactant is polysorbate 80, and wherein the aqueous liquid carrier is distilled water, hypertonic saline or isotonic saline.

7. The pharmaceutical composition according to claim 6 wherein the hypertonic saline is from 1% to 7% (w/v) sodium chloride.

8. The pharmaceutical composition according to claim 6 wherein the non-ionic surfactant is ultrapure polysorbate 80, and wherein the aqueous liquid carrier is isotonic saline.

9. The pharmaceutical composition according to claim 1 wherein the osmolality of the composition is in the range of 200-700 mOsm/kg.

10. The pharmaceutical composition according to claim 1 wherein the osmolality of the composition is in the range of 300-400 mOsm/kg.

11. The pharmaceutical composition according to claim 1 wherein the nonionic surfactant is in the range of 0.001% to 5% (v/v) of the total composition and the amount of clofazimine is in the range of 0.1% to 20% (w/v) of the total composition.

12. The pharmaceutical composition according to claim 1 , prepared by a process comprising the following steps:

(1) homogenization of a suspension of clofazimine, the nonionic surfactant and water to obtain a suspension comprising clofazimine of an appropriate particle size,

(2) adjusting the pH of the suspension resulting from (1) to a pH of between pH 5.5 and pH 7.5, and

(3) adjusting the sodium chloride concentration to an appropriate concentration and

(4) adjusting the osmolality to an appropriate level.

13. The pharmaceutical composition according to claim 12 wherein the pH is adjusted to 7.4, and the sodium chloride concentration is adjusted to 154 mM sodium chloride.

14. The pharmaceutical composition according to claim 12 , wherein the homogenization in step (1) is carried out by high pressure homogenization, high shear homogenization, wet milling, ultrasonic homogenization, or a combination of such processes.

15. The pharmaceutical composition according to claim 12 wherein the homogenization of clofazimine is carried out in multiple steps of homogenization.

16. The pharmaceutical composition according to claim 12 wherein appropriate particle size of the clofazimine are particles having a mean size of less than 5 μm and D90 less than 6 μm.

17. The pharmaceutical composition according to claim 12 wherein the appropriate particle size of the clofazimine are particles having a mean size of less than 2 μm and D90 less than 3 μm.

18. The pharmaceutical combination in the form of an aerosol for inhalation, prepared by aerosolization of the composition according to claim 1 by a nebulizing device selected from an ultrasonic nebulizer, an electron spray nebulizer, a vibrating membrane nebulizer, a jet nebulizer and a mechanical soft mist inhaler, and

wherein the aerosol particles produced by the nebulizing device have a mass median aerodynamic diameter of 1 to 5 μm.

19. A system for use in providing antibiotic activity when treating or providing prophylaxis against a pulmonary infection caused by mycobacteria or other gram-positive bacteria, wherein the system comprises:

1) A nebulized pharmaceutical combination comprising:

a therapeutically effective dose of clofazimine;

a nonionic surfactant with an Hydrophilic-Lipophilic Balance value of greater than 10;

an aqueous liquid carrier selected from water, isotonic saline, buffered saline and aqueous electrolyte solutions;

a mucolytic and/or biofilm destructing agent; and

2) a nebulizer, wherein the clofazimine is present in the form of a suspension; and,

wherein the aerosol particles produced by the system have a mass median aerodynamic diameter of 1 to 5 μm.

20. A method of treatment or prophylaxis of a pulmonary infection, in a patient in need thereof, comprising administering by inhalation a composition according to claim 1 .

21. The method of treatment or prophylaxis according to claim 20 , wherein the infection is caused by a species of the genus Mycobacterium selected from nontuberculous mycobacteria and Mycobacterium tuberculosis complex, and a combination thereof.

22. The method of treatment or prophylaxis according to claim 21 wherein the nontuberculous Mycobacterium is selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessus , and Mycobacterium leprae , and a combination thereof.

23. The method of treatment or prophylaxis according to claim 21 wherein the infection is an opportunistic infection, selected from MAC pulmonary disease and nontuberculous infection, in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immune deficiency syndrome.

24. The method of treatment or prophylaxis according to claim 23 wherein the infection is an opportunistic nontuberculous mycobacteria infection in a patient with cystic fibrosis.

25. A method of treatment or prophylaxis of a pulmonary infection caused by mycobacteria or other gram positive bacteria, in a patient in need thereof, comprising administering by inhalation a composition according to claim 1 , before, simultaneously, or subsequently to the administration of an agent selected from bedaquiline, or a pharmaceutically acceptable salt of derivative thereof, cefoxitine, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-amino salicylate, and mixtures thereof.

26. The method of treatment or prophylaxis according to claim 25 , wherein the agent is bedaquiline or amikacin.

27. The method of treatment or prophylaxis according to claim 26 , wherein the agent is bedaquiline.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072445/0769 →
Continuity (2)
Continuation 17181448 · Feb 22, 2021
Related Publication 20240000779A1 · Jan 4, 2024
References Cited (99)
US 6514482B1 · Bartus et al. · 2003 [cited by applicant]
US 8940683B2 · Levitt · 2015 [cited by applicant]
US 9844548B2 · Gonda et al. · 2017 [cited by applicant]
US 9907754B2 · Farrow et al. · 2018 [cited by applicant]
US 9987227B2 · Cipolla et al. · 2018 [cited by applicant]
US 10328216B2 · Boeckl et al. · 2019 [cited by applicant]
US 10392388B2 · Ong et al. · 2019 [cited by applicant]
US 10500159B2 · Amoro et al. · 2019 [cited by applicant]
US 10550389B2 · Levitt · 2020 [cited by applicant]
US 10624893B2 · Ballell Pages et al. · 2020 [cited by applicant]
US 10905660B2 · O'Neil · 2021 [cited by applicant]
US 11793808B2 · Hofmann · 2023 [cited by examiner]
US 20010046526A1 · Greenfelder · 2001 [cited by applicant]
US 20080038363A1 · Zaffaroni et al. · 2008 [cited by applicant]
US 20090162441A1 · Bartus et al. · 2009 [cited by applicant]
US 20090269396A1 · Cipolla et al. · 2009 [cited by applicant]
US 20090312380A1 · Becker · 2009 [cited by applicant]
US 20100028428A1 · Hegyi et al. · 2010 [cited by applicant]
US 20100258118A1 · Morton · 2010 [cited by applicant]
US 20140220091A1 · Tofail et al. · 2014 [cited by applicant]
US 20160039823A1 · Ong et al. · 2016 [cited by applicant]
US 20160207969A1 · Lee et al. · 2016 [cited by applicant]
US 20160220710A1 · Keswani et al. · 2016 [cited by applicant]
US 20160251380A1 · Alley et al. · 2016 [cited by applicant]
US 20170056345A1 · Timmins et al. · 2017 [cited by applicant]
US 20170209530A1 · Heng et al. · 2017 [cited by applicant]
US 20170252446A1 · Voigt et al. · 2017 [cited by applicant]
US 20170333427A1 · Ho et al. · 2017 [cited by applicant]
US 20170348254A1 · O'Neil · 2017 [cited by applicant]
US 20180000810A1 · Gupta et al. · 2018 [cited by applicant]
US 20180250299A1 · Kalman · 2018 [cited by applicant]
US 20190030026A1 · Ho et al. · 2019 [cited by applicant]
US 20190175501A1 · O'Neil · 2019 [cited by applicant]
US 20190262472A1 · Hudson et al. · 2019 [cited by applicant]
US 20190282502A1 · Boeckl et al. · 2019 [cited by applicant]
US 20190307760A1 · Reiling et al. · 2019 [cited by applicant]
US 20190350928A1 · Sanyal et al. · 2019 [cited by applicant]
US 20200009116A1 · Borody · 2020 [cited by applicant]
US 20200009143A1 · Timmins et al. · 2020 [cited by applicant]
US 20200046650A1 · Baker et al. · 2020 [cited by applicant]
US 20200069588A1 · Zhou et al. · 2020 [cited by applicant]
US 20200297626A1 · Smyth et al. · 2020 [cited by applicant]
US 20200368312A1 · Heckler et al. · 2020 [cited by applicant]
US 20210085620A1 · Andries et al. · 2021 [cited by applicant]
US 20210100786A1 · Malhotra et al. · 2021 [cited by applicant]
AU 2012238199A1 · 2012 [cited by applicant]
AU 2017200228 · 2017 [cited by applicant]
IN 202017013676A · 2020 [cited by applicant]
WO 2012073025A1 · 2012 [cited by applicant]
WO 2017127641A1 · 2017 [cited by applicant]
WO 2018217800A1 · 2018 [cited by applicant]
WO 2019070693A1 · 2019 [cited by applicant]
WO 2020023614A1 · 2020 [cited by applicant]
WO 2020040818A1 · 2020 [cited by applicant]
WO 2020106787A1 · 2020 [cited by applicant]
WO 2020144197A1 · 2020 [cited by applicant]
WO 2020169747A1 · 2020 [cited by applicant]
WO 2020172594A1 · 2020 [cited by applicant]
Verma et al., “Inhaled Microparticles Containing Clofazimine Are Efficacious in Treatment of Experimental Tuberculosis in Mice”, Antimicrobial Agents and Chemotherapy Journal, Feb. 2013, vol. 57, pp. 1050-1052. [cited by applicant]
Bannigan et al., “Investigation into the Solid and Solution Properties of Known and Novel Polymorphs of the Antimicrobial Molecule Clofazimine”, Crystal Growth Design, Nov. 7, 2016, vol. 16, pp. 7240-7250. [cited by applicant]
Brunaugh et al., “Excipient-Free Pulmonary Delivery and Macrophage Targeting of Clofazimine via Air Jet Micronization” Nov. 6, 2017;14(11):4019-4031. [cited by applicant]
Pilcer et al. “Formulation strategy and use of excipients in pulmonary drug delivery” Int J Pharm. Jun. 15, 2010;392(1-2):1-19. [cited by applicant]
Murashov et al. “Synthesis and Characterization of a Biomimetic Formulation of Clofazimine Hydrochloride Microcrystals for Parenteral Administration” Pharmaceutics, Nov. 17, 2018;10(4):238, pp. 1-14. [cited by applicant]
International Search Report mailed on Jun. 27, 2019 for International Application No. PCT/US2019/025538 filed on Apr. 3, 2019. [cited by applicant]
Adler-Shohet et al., “2277. Clofazimine for Treatment of [cited by applicant]
Ruth et al., “A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria”, Journal of Antimicrobial Chemotherapy, Apr. 1, 2019;74(4),pp. 1-9. [cited by applicant]
Berry et al., “A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity”, Nature, No. 4568, May 18, 1957, pp. 1013-1015. [cited by applicant]
Schwartz et al. “Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis”, Disease, Microbial Drug Resistance, vol. 00, No. 00,… [cited by applicant]
Barry et al., “Antituberculosis Activity in the Phenazine Series. Isomeric Pigments Obtained by Oxidation of 0-Phenylenediamine Derivatives”, Laboratories of the Medical Research Council of Ireland, Trinity College, Dub… [cited by applicant]
Diacon et al., “Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline” Am J Respir Crit Care Med. Apr. 15, 2015;191(8), pp. 943-953. [cited by applicant]
Roy et al., “Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice in vivo. II. Micronucleus test in bone marrow and hepatocytes”, Mutation Research, 241 (1990), pp. 169-173. [cited by applicant]
Shen et al., “High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria”, Int J Antimicrob Agents. Apr. 2010;35(4), pp. 400-404. [cited by applicant]
Singh et al., “In vitro evaluation of a new drug combination against clinical isolates belonging to the [cited by applicant]
Ingen et al., “In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease”, Antimicrobial Agents and Chemotherapy, Dec. 2012 vol. 56 No. 12, pp. 6324-6327. [cited by applicant]
Janulionis et al., “Lack of Activity of Orally Administered Clofazimine against Intracellular [cited by applicant]
Yawalkar et al., “Lamprene ( Clofazimine) in Leprosy”, Lepr Rev. Jun. 1979;50(2) pp. 135-144. [cited by applicant]
Cholo et al., “Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline”, Antimicrob Chemother 2017; 72: pp. 338-353. [cited by applicant]
Feng et al., “Metabolism of Clofazimine in Leprosy Patients”, Drug Metab Dispos. Nov.-Dec. 1981;9(6):pp. 521-524. [cited by applicant]
Feng et al., “A New Urinary Metabolite of Clofazimine in Leprosy Patients”, Drug Metab Dispos. May-Jun. 1982;10(3): pp. 286-288. [cited by applicant]
Yoon et al., “Phagocytosed Clofazimine Biocrystals can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion”, Mol Pharm. Jul. 6, 2015; 12(7): pp. 1-22. [cited by applicant]
Mack R. Holdiness, “Clinical Pharmacokinetics of Clofazimine a Review”, Clinical Pharmacokinetics 16: 1989, pp. 74-85. [cited by applicant]
Charles A. Peloquin, “Clinical Pharmacology of Clofazimine”, Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and the Emerging Pathogens Institute University of Florida. [cited by applicant]
Martiniano et al., “Clinical Significance of a First Positive Nontuberculous Mycobacteria Culture in Cystic Fibrosis”, Ann Am Thorac Soc. Jan. 2014;11(1):36-44. [cited by applicant]
Yoon et al., “Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease”, Int J Tuberc Lung Dis 21(9):996-1001. [cited by applicant]
Yoon et al., “Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production to Induce a Systemic Anti-Inflammatory State”, Antimicrobial Agents and Chemotherapy, Jun. 2016 v… [cited by applicant]
Wang et al., “Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China”, Antimicrobial Agents and Chemotherapy, Apr. 2018 vol. 62 Issue 4 e02149-17, pp. 1-9. [cited by applicant]
Ferro et al., “Clofazimine Prevents the Regrowth of [cited by applicant]
O'Driscoll et al., “Clofazimine”, Analytical Profiles of Drug Substances and Excipients—vol. 21, 1992, pp. 75-108. [cited by applicant]
Sangana et al., “Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches”, Drug Metab Dispos. Jan. 2018;46(1), pp. 26-32. [cited by applicant]
Das et al., “Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice in vivo. I. Chromosome analysis in bone marrow and spermatocytes”, Mutation Research, 241 (1990), pp. 161-168. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion mailed on May 10, 2022 for International Application No. PCT/US2020/058447 filed on Nov. 1, 2020. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion mailed on Oct. 27, 2022 for International Application No. PCT/US2021/030155 filed on Apr. 30, 2021. [cited by applicant]
Banaschewski et al., “Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections”, Journal of Cystic Fibrosis, 2019, vol. 18, No. 5, pp. 714-720. [cited by applicant]
Maartens et al., “Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis”, Int J Tuberc Lung Dis. Jan. 1, 2018;22(1): pp. 26-30. [cited by applicant]
Martiniano et al., “Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection”, Chest Infections, Oct. 2017;152(4): pp. 800-809. [cited by applicant]
Aznar et al., “Safety and effectiveness of clofazimine in nontuberculous mycobacterial lung disease”, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, vol. 2, 2018, Issue 2, pages. [cited by applicant]
Bald et al., “Targeting Energy Metabolism in [cited by applicant]
Peters et al., “Preparation of a Clofazimine Nanosuspension for intravenous use and evaluation of its Therapeutic Efficacy in Murine [cited by applicant]
Japanese Notice of Reasons for Refusal mailed Dec. 6, 2022 for JP Application No. 2021-510120 filed on Apr. 3, 2019. [cited by applicant]